Evidence map›Paper›PMID 38665868›Full record

ArticleBiochemia medica2024

A case report of biclonal immunoglobulin D lambda/lambda multiple myeloma in patient with liver echinococcosis.

Andrea Prce, Željka Dunđerović, Ivanka Mikulić, Vinka Mikulić, Kristina Ljubić, Ana Ćuk, Ante Bogut, Josip Petrović, Mile Volarić, Tomislav Čolak and 1 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Biochemia medica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Andrea PrceDepartment of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Željka DunđerovićDepartment of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Ivanka MikulićDepartment of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Vinka MikulićDepartment of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Kristina LjubićDepartment of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Ana ĆukDepartment of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Ante BogutDepartment of Gastroenterology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Josip PetrovićDepartment of Hematology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Mile VolarićDepartment of Gastroenterology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Tomislav ČolakDepartment of Hematology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
Fila RagužDepartment of Nephrology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
University Clinical Hospital Mostar · BAUniversity of Mostar · BA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Less than 2% of all symptomatic multiple myeloma (MM) has immunoglobulin D (IgD) as monoclonal protein. Biclonal gammopathy is much rarer. At the time of diagnosis, disease is often in advanced stage, including renal failure, anemia, hypercalcemia and lytic bone lesions. Due to the rarity of myeloma itself, but also due to the fact that anti-IgD antisera is not used in routine practice, there are only a few reports of IgD MM described in the literature. This case report describes a patient with IgD lambda MM with anemia and renal failure. Anemia, renal failure, and > 80 percent plasma cells in bone biopsy in our patient with IgD lambda MM meets International Myeloma Working Group criteria for diagnosis of MM. The patient clinical course was similar to other patients with IgD MM. The final result of serum protein immunofixation (s-IFE) showed IgD lambda and free lambda monoclonal bands. To prevent misdiagnosis, it is necessary to use anti-IgD and anti-IgE antisera whenever the serum protein immunofixation with IgA, IgM, IgG, kappa and lambda antiserums shows a kappa or lambda monoclonal band without monoclonal band in heavy chain.

Indexed as

Immunoglobulin DImmunoglobulin lambda-ChainsMultiple MyelomaHumansMaleMiddle AgedImmunoglobulin DImmunoglobulin lambda-Chainsimmunoglobulin Dmonoclonal gammopathymultiple myelomaserum protein immunofixation

Identifiers

PMID38665868
PMCPMC11042564
OpenAlexW4394846062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.